Company intelligence / Profile preview

Alkalon

Glostrup, Denmark

Ownership: Private
Development stage: Other

Overview

Alkalon has developed generic nicotine replacement chewing gum that matches the release profile of Nicorette and has commercial approvals in multiple European countries. Its main product (nicotine chewing gum) is marketed via partner companies. The company offers additional contract research and product development services in medicated chewing gum.

Therapeutic areas: Psychiatry
Modalities: Small moleculeMedical chewing gum
Industry: Biotech

Partnerships

Orifarmmultiple unnamed European pharma supply/license partners

Beyond the preview

Go deeper on Alkalon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alkalon.

Explore the full profile